Medisse B.V., an Ede, the Netherlands-based closed a €2.6m Series B equity financing round.
Backers included new investor IIG, which joined existing investors BioGeneration Ventures and Omnes Capital in the round. In addition, the company will receive an innovation credit from the Dutch Ministry of Economic Affairs.
Founded in 2009 and led by Sandra de Vos, CEO, Medisse develops resorbable implants for soft tissue applications, based on a patented flexible polymer platform.
The company intends to use the capital for the clinical trial of its lead product FlexiSurge® Adhesion Barrier, aiming to obtain a CE mark, as well as for development of other devices.